Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG814N)

Drug Name
Saquinavir Drug Info
Synonyms
Fortovase; Invirase; ROC; SQV; Saguinavir; Ro 318959; Fortovase (TN); Fortovase(TM); Invirase (TN); Ro 31-8959; Invirase(TM)(monomesylate); Ro-31-8959; Saquinavir (JAN/USP/INN); QNC-ASN-HPH-DIQ-NTB; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Cross-matching ID
PubChem CID
441243
ChEBI ID
CHEMBL114
CAS Number
CAS 127779-20-8
TTD Drug ID
DMG814N
VARIDT Drug ID
DR00309
INTEDE Drug ID
DR1462
ACDINA Drug ID
D00615

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Human immunodeficiency virus Protease (HIV PR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [17]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [18]
Atazanavir DMSYRBX Human immunodeficiency virus infection 1C62 Approved [19]
Amprenavir DMLMXE0 Human immunodeficiency virus infection 1C62 Approved [20]
Darunavir DMN3GCH Human immunodeficiency virus infection 1C62 Approved [21]
Tipranavir DM8HJX6 Human immunodeficiency virus infection 1C62 Approved [22]
Fosamprenavir DM4W9B3 Human immunodeficiency virus infection 1C62 Approved [23]
BI 201335 DM3MXT8 Hepatitis C virus infection 1E51.1 Phase 3 [24]
BMS 650032 DMQI43G Hepatitis C virus infection 1E51.1 Phase 2 [25]
Danoprevir DM20MDU Hepatitis C virus infection 1E51.1 Phase 2 [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Multidrug resistance-associated protein 1 (ABCC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [27]
Methotrexate DM2TEOL Anterior urethra cancer Approved [28]
Folic Acid DMEMBJC Colorectal carcinoma Approved [29]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [30]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [31]
Verapamil DMA7PEW Angina pectoris BA40 Approved [32]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [33]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [34]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [35]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [37]
Methotrexate DM2TEOL Anterior urethra cancer Approved [38]
Folic Acid DMEMBJC Colorectal carcinoma Approved [39]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [40]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [41]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [42]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [43]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [44]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [45]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [32]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [47]
Methotrexate DM2TEOL Anterior urethra cancer Approved [48]
Folic Acid DMEMBJC Colorectal carcinoma Approved [49]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [48]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [48]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [50]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [48]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [51]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Breast cancer resistance protein (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [53]
Methotrexate DM2TEOL Anterior urethra cancer Approved [54]
Folic Acid DMEMBJC Colorectal carcinoma Approved [55]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [56]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [57]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [58]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [59]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [58]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [60]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [62]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [7]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [63]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [64]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [63]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [65]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [66]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [67]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [68]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporting polypeptide 1A2 (SLCO1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [69]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [70]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [71]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [72]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [73]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [74]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [75]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [76]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [77]
Labetalol DMK8U72 Hypertension BA00-BA04 Approved [78]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [79]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [80]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [81]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [82]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [83]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [84]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [85]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [86]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [80]
Verapamil DMA7PEW Angina pectoris BA40 Approved [87]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [88]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [89]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [90]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [83]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [87]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [91]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [92]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [93]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [94]
Propranolol DM79NTF Angina pectoris BA40 Approved [95]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [96]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [97]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [98]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [99]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [100]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [101]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [102]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [103]
Verapamil DMA7PEW Angina pectoris BA40 Approved [104]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [99]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [105]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [99]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [99]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [99]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [106]
Verapamil DMA7PEW Angina pectoris BA40 Approved [107]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [99]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [99]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [99]
Metronidazole DMTIVEN Abscess Approved [108]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier organic anion transporter family member 1A2 (SLCO1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trospium chloride DM32XZT Discovery agent N.A. Approved [109]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [110]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [111]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [112]
Testosterone enanthate DMB6871 N. A. N. A. Approved [113]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [114]
Cholecalciferol DMGU74E Adult acute monocytic leukemia Approved [115]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [116]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [117]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [118]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [13]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [119]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [119]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [120]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [13]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [119]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [121]
Gefitinib DM15F0X Colon adenocarcinoma Approved [13]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [122]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Albumin (ALB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [123]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [124]
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [125]
Diazepam DM08E9O Alcohol withdrawal Approved [126]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [127]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [128]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [129]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [130]
Methotrexate DM2TEOL Anterior urethra cancer Approved [131]
Quercetin DM3NC4M Obesity 5B81 Approved [132]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By HLA class II histocompatibility antigen, DO alpha chain (HLA-DOA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefitinib DM15F0X Colon adenocarcinoma Approved [15]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [133]
Indapamide DMGN1PW Edema MG29 Approved [15]
Bortezomib DMNO38U Leukemia Approved [134]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [15]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [117]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [135]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [136]
acetaldehyde DMJFKG4 Discovery agent N.A. Investigative [137]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [138]
Quercetin DM3NC4M Obesity 5B81 Approved [139]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [138]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [140]
Pyrazinamide DM4IF32 Meningeal tuberculosis Approved [141]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [142]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [143]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [138]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [144]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [145]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By HLA class I histocompatibility antigen, alpha chain F (HLA-F)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefitinib DM15F0X Colon adenocarcinoma Approved [15]
Selenium DM25CGV N. A. N. A. Approved [146]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [15]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [147]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [148]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [149]
Repaglinide DM5SXUV Diabetic complication 5A2Y Approved [15]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [150]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [151]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [152]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Synaptic vesicle glycoprotein 2B (SV2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [133]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [153]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [154]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [155]
Sulforaphane DMQY3L0 Skin disease EA00-EM0Z Investigative [156]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Protease (HIV PR) TT5FNQT POL_HV1B1 Inhibitor [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [3]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [4]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [5]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [12]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [13]
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Gene/Protein Processing [14]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Gene/Protein Processing [15]
HLA class II histocompatibility antigen, DO alpha chain (HLA-DOA) OTZE5Q7R DOA_HUMAN Gene/Protein Processing [15]
Solute carrier organic anion transporter family member 1A2 (SLCO1A2) OTO70C5O SO1A2_HUMAN Regulation of Drug Effects [4]
Synaptic vesicle glycoprotein 2B (SV2B) OTAO5WIU SV2B_HUMAN Drug Response [16]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4813).
2 PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
3 Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
4 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
5 Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62.
6 Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010 Dec;115(6):1495-507.
7 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
8 Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.
9 Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009 Oct;29(10):1175-81.
10 Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
11 Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
12 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
13 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
14 The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells. Gynecol Oncol. 2009 Mar;112(3):623-30. doi: 10.1016/j.ygyno.2008.11.028. Epub 2009 Jan 15.
15 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
16 Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
17 Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
18 Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
19 Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
20 Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
21 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
23 Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
24 2011 Pipeline of Boehringer Ingelheim Pharma.
25 2011 Pipeline of Bristol-Myers Squibb.
26 2011 Pipeline of InterMune.
27 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
28 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
29 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
30 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
31 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
32 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
33 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
34 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
35 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
36 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
37 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
38 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
39 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
40 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
41 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
42 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
43 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
44 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
45 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
46 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
47 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
48 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
49 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
50 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
51 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
52 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
53 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
54 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
55 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
56 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
57 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
58 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
59 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
60 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
61 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
62 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
63 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
64 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
65 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
66 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
67 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
68 FDA Drug Development and Drug Interactions
69 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
70 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
71 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
72 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
73 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
74 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
75 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
76 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
77 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
78 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
79 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
80 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
81 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
82 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
83 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
84 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
85 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
86 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
87 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
88 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
89 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
90 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
91 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
92 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
93 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
94 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
95 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
96 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
97 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
98 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
99 Drug Interactions Flockhart Table
100 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
101 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
102 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
103 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
104 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
105 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
106 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
107 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
108 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
109 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
110 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
111 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
112 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
113 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
114 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
115 The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. Mol Pharmacol. 2012 Jul;82(1):37-46. doi: 10.1124/mol.112.077909. Epub 2012 Apr 3.
116 UDCA and CDCA alleviate 17-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25. doi: 10.1016/j.taap.2016.10.011. Epub 2016 Oct 12.
117 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
118 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
119 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
120 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
121 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
122 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
123 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
124 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
125 A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
126 The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
127 Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
128 Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
129 Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
130 [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
131 Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
132 Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
133 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
134 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
135 Inter- and intra-laboratory study to determine the reproducibility of toxicogenomics datasets. Toxicology. 2011 Nov 28;290(1):50-8.
136 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
137 Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
138 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
139 Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
140 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
141 Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2-ATF4-CHOP pathway. Toxicology. 2017 Mar 1;378:65-75. doi: 10.1016/j.tox.2017.01.002. Epub 2017 Jan 4.
142 Glucosamine-induced endoplasmic reticulum stress attenuates apolipoprotein B100 synthesis via PERK signaling. J Lipid Res. 2009 Sep;50(9):1814-23. doi: 10.1194/jlr.M800343-JLR200. Epub 2009 Apr 21.
143 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
144 Arsenic trioxide initiates ER stress responses, perturbs calcium signalling and promotes apoptosis in human lens epithelial cells. Exp Eye Res. 2007 Dec;85(6):825-35. doi: 10.1016/j.exer.2007.08.018. Epub 2007 Aug 29.
145 Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.
146 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
147 Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
148 Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
149 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
150 Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
151 The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
152 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
153 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
154 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
155 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
156 Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047. doi: 10.1016/j.fct.2019.111047. Epub 2019 Dec 12.